Breast Cancer
Breast cancer is a malignant tumor that originates from tissues of the breast. It is the second leading cause of cancer death, surpassed only by lung cancer.
90%
of Proton Therapy cases result in good to excellent cosmetic results for partial breast radiation patients at 5 years
42%
Reduced risk of cardiac side effects
98%
Patient Satisfaction Rating
Proton Therapy Treatment for Breast Cancer
The breast cancer tumor usually occurs in the lobules and ducts of the breast, which are used in the production and delivery of breast milk. Breast cancer is the most common cancer among women aside from skin cancer. Men are also susceptible to breast cancer, although the disease is rare among males.
As with other cancers, the best possible outcomes for breast cancer treatment come through early breast cancer care.Proton therapy has unique attributes that reduce radiation exposure to normal, healthy organs.1,2 This is especially important in left-sided breast cancer, as the cancer is close to critical organs such as the heart and the lungs.
Clinical Investigation-Partial Breast Radiation With Proton Beam: 5-Year Results With Cosmetic Outcomes
1 MacDonald S, Specht M, Isakoff S, et al. Prospective pilot study of proton radiation therapy for invasive carcinoma of the breast following mastectomy in patients with unfavorable anatomy – first reported clinical experience. Int J Radiat Oncol. 2012;84(Suppl 3):S113-S114. Abstract 281
2 Moon SH, Shin KH, Kim TH, et al. Dosimetric comparison of four different external beam partial breast irradiation techniques: three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, helical tomotherapy, and proton beam therapy. Radiother Oncol. 2009;90:66-73.
- Symptoms
- Diagnosis
- Treatment
Request Information
For information or to schedule a consultation, contact us to speak with a Care Coordinator.
Partner With Us
For general information or to learn about our collaborative partnerships, future developments, ProNova proton therapy system, or investment opportunities, contact us.